News Headline Summary

Alexion (ALXN) says new data shows clinical benefits over 10 years of Soliris

- Says data shows Soliris significantly cuts Thromboembolism risk.

Reaction details:

- Co. shares spike 0.45% higher in immediate reaction to the news from USD 93.13 to USD 93.58.

Print 15:32, 10 Dec 2012 - US Equities - Source: Newswires